Fig. 2

Correlations between SpHe-comut status and TMB, NAL, and MSI-H. A, B ROC curves of the number of comutated signaling pathways to predict higher TMB (A) and higher NAL levels (B) from TCGA. C, D Multiple linear regression β coefficients between six signaling pathways and TMB (C) and NAL (D). E, F Comparison of TMB (E) and NAL (F) between patients with Sp-ECMRI comutation, He-ECMRI comutation, Sp-He comutation, and other comutations. G, H Comparison of TMB (G) and NAL (H) between SpHe-comut⁺ and SpHe-comut⁻ groups in tumors with the approved indication of immune therapy. I Overlapping of patients with SpHe-comut⁺ and MSI-H. J Comparison of TMB in different combinations of SpHe-comut status (SpHe-comut⁺ and SpHe-comut⁻) and MSI status (MSI-H and MSS) groups. K Waterfall plot of two signature mutation pathways and the mutation genes involved in these pathways. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; *****p < 0.00001. BLCA bladder urothelial carcinoma, HNSC head and neck squamous cell carcinoma, KIRC kidney renal clear cell carcinoma, LIHC liver hepatocellular carcinoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma